Search

everythinglearnresearchcommunity

for

Search:↓

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Talquetamab may cause hair loss and skin issues.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Tislelizumab can cause cutaneous lupus erythematosus.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Biologics for severe asthma have known side effects, but some new risks need more study.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Omalizumab can cause temporary hair loss but still works well for chronic urticaria.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Blocking IL-8 can reduce skin rashes from cancer treatment.

A woman with IgG/IgA pemphigus was treated successfully with dapsone and steroids.

Tofacitinib is a promising treatment for children with rheumatic diseases.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.